Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib in Relapsed/Refractory PTCL
NCT03372057Phase 2Completed
- Sponsor
- Secura Bio
- Start
- Feb 2018
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of duvelisib in peripheral T-cell lymphoma (PTCL), sponsored by Secura Bio. Started Feb 2018; status: completed.
02
Drugs
duvelisib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT03372057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03372057.